Venous stenosis, as the result of neointimal hyperplasia, is the major cause of hemodialysis vascular access dysfunction, and there has been a paucity of novel therapeutic interventions in this field. This is in marked contrast to a recent plethora of targeted interventions for the treatment of arterial neointimal hyperplasia after coronary angioplasty. There has been a relative lack of cellular and molecular research that focuses on venous neointimal hyperplasia in the specific setting of hemodialysis vascular access. In addition, there have been inadequate efforts by the nephrology community to translate the recent advances in molecular and interventional cardiology into therapies for hemodialysis vascular access. This article reviews recent concepts in the pathogenesis of vascular stenosis that could potentially be applied in the setting of hemodialysis vascular access dysfunction.